Blood pressure, C-reactive protein, and risk of future cardiovascular events

Area of Science:

• Cardiovascular Medicine
• Inflammation Research
• Public Health

Background:

• Emerging evidence links elevated blood pressure to vascular inflammation.
• C-reactive protein (CRP) is a key inflammatory marker associated with cardiovascular disease.
• Understanding the interplay between blood pressure and inflammation is crucial for cardiovascular risk assessment.

Purpose of the Study:

• To investigate the relationship between blood pressure, CRP levels, and the incidence of first cardiovascular events in women.
• To determine if CRP provides incremental prognostic value for cardiovascular events across different blood pressure categories.
• To assess the combined and independent contributions of blood pressure and CRP to cardiovascular risk.

Main Methods:

• Prospective cohort study involving 15,215 women.
• Baseline assessment of blood pressure and C-reactive protein (CRP) levels.
• Follow-up for incident first cardiovascular events over a median of 8.1 years.
• Statistical analyses including cross-sectional and prospective analyses, hazard ratios, and risk factor adjustments.

Main Results:

• A significant positive trend was observed between increasing blood pressure categories and median CRP levels at baseline (P < 0.0001).
• Both elevated CRP levels (≥3 mg/L) and higher blood pressure categories were independent predictors of future cardiovascular events.
• The combination of high blood pressure (≥160/95 mm Hg) and high CRP (≥3 mg/L) was associated with a substantially increased hazard ratio (8.31) for cardiovascular events.
• Risk factor-adjusted analyses showed additive effects: high CRP/low blood pressure (HR 1.87), low CRP/high blood pressure (HR 2.54), and high CRP/high blood pressure (HR 3.27).

Conclusions:

• Blood pressure and CRP are independent determinants of cardiovascular risk.
• The predictive value of blood pressure and CRP for cardiovascular events is additive.
• Measuring both blood pressure and CRP can enhance cardiovascular risk stratification.